ArticleJournal of immunology (Baltimore, Md. : 1950)2016
Cutting Edge: CD99 Is a Novel Therapeutic Target for Control of T Cell-Mediated Central Nervous System Autoimmune Disease.
Article in Journal of immunology (Baltimore, Md. : 1950), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 34 citations in OpenAlex.
- Single-cell analysis of skin and blood reveals systemic immune responses to ultraviolet B and their impairment in MS.Journal of neuroinflammation · 2026Trial
- Single-Cell Profiling Reveals Clonally Expanded CX3CR1Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Integrative Bioinformatics Analyses Reveal X Chromosome Inactivation Escape Genes Dosage Dysregulation Is the Primary Contributor to Turner Syndrome.Iranian journal of biotechnology · 2026Article
- Neutrophil extracellular traps-associated candidate genes in IgA vasculitis: an exploratory multi-omics analysis integrating transcriptomics and Mendelian randomization.Pediatric rheumatology online journal · 2026Article
- CD99-targeted immunomagnetic negative selection: A novel strategy for high-purity pancreatic islet isolation in murine models.PloS one · 2026Article
- Trace Amine-associated Receptors (TAARs): Candidate Targets in the Treatment of Bipolar Disorders.Actas espanolas de psiquiatria · 2025Review
- Biomarkers of immune dysregulation and posttreatment inflammation in spinal muscular atrophy.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- CD99-mediated immunological synapse formation potentiates CAR-T cell function.Nature communications · 2025Article
- Nutritional Modulation of Impaired Blood-Brain Barrier Integrity and Function in Major Depression.International journal of molecular sciences · 2025Review
- Integration of Single-Cell RNA Sequencing Data and Bulk Sequencing Data to Characterise the CD8+ T-Cell Exhaustion Mediated Immune Microenvironment in CRC.Journal of cellular and molecular medicine · 2025Article
- CD99: A Key Regulator in Immune Response and Tumor Microenvironment.Biomolecules · 2025Review
- Unveiling the Mysteries of the Blood-brain Barrier: The Problem of the Brain/spinal Pharmacotherapy.Central nervous system agents in medicinal chemistry · 2025Review
- Sex- and species-specific contribution of CD99 to T cell costimulation during multiple sclerosis.Biology of sex differences · 2024Article
- Blood brain barrier and inflammation in depression.Neurobiology of disease · 2022Article
- Escape from X chromosome inactivation and female bias of autoimmune diseases.Molecular medicine (Cambridge, Mass.) · 2020Review
- A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity.Fluids and barriers of the CNS · 2020Review
- Vitamin D/CD46 Crosstalk in Human T Cells in Multiple Sclerosis.Frontiers in immunology · 2020Article
- Immune cell trafficking across the blood-brain barrier in the absence and presence of neuroinflammation.Vascular biology (Bristol, England) · 2020Review
- Structure and Junctional Complexes of Endothelial, Epithelial and Glial Brain Barriers.International journal of molecular sciences · 2019Review
- Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99.Oncogene · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Leukocyte trafficking into the CNS is a prominent feature driving the immunopathogenesis of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. Blocking the recruitment of inflammatory leukocytes into the CNS represents an exploitable therapeutic target; however, the adhesion molecules that specifically regulate the step of leukocyte diapedesis into the CNS remain poorly understood. We report that CD99 is critical for lymphocyte transmigration without affecting adhesion in a human blood-brain barrier model. CD99 blockade in vivo ameliorated experimental autoimmune encephalomyelitis and decreased the accumulation of CNS inflammatory infiltrates, including dendritic cells, B cells, and CD4(+) and CD8(+) T cells. Anti-CD99 therapy was effective when administered after the onset of disease symptoms and blocked relapse when administered therapeutically after disease symptoms had recurred. These findings underscore an important role for CD99 in the pathogenesis of CNS autoimmunity and suggest that it may serve as a novel therapeutic target for controlling neuroinflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.